Download PDF
Pharmacopsychiatry 2016; 49(01): 14-17
DOI: 10.1055/s-0035-1565134
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Expression of Glutamate Transporters in Alcohol Withdrawal

S. Ozsoy
1   Department of Psychiatry, Erciyes University School of Medicine, Kayseri/Turkey
,
A. Asdemir
1   Department of Psychiatry, Erciyes University School of Medicine, Kayseri/Turkey
,
O. Karaaslan
2   Department of Psychiatry, Yozgat State Hospital, Yozgat/Turkey
,
H. Akalin
3   Department of Medical Genetics, Erciyes University School of Medicine, Kayseri/Turkey
,
Y. Ozkul
3   Department of Medical Genetics, Erciyes University School of Medicine, Kayseri/Turkey
,
E. Esel
1   Department of Psychiatry, Erciyes University School of Medicine, Kayseri/Turkey
› Author Affiliations
Further Information

Publication History

received 16 June 2015
revised 26 August 2015

accepted 05 October 2015

Publication Date:
16 November 2015 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction: The study aimed to investigate the expression of glutamate transporters during withdrawal in the alcohol-dependent patients.

Method: The study consisted of 20 male inpatient alcoholics during the withdrawal period and 20 healthy controls. Expressions of glutamate transporters, namely the excitatory amino acid transporter 2 (EAAT2) and EAAT3, in white blood cells were measured with the real-time polymerase chain reaction (RT-PCR) method in early (first day) and late (28th day) withdrawal in alcoholic patients and once in the controls.

Results: EAAT2 and EAAT3 expressions in the patients during both early and late withdrawal were higher than those of the controls. There was no difference in the EAAT2 and EAAT3 levels of the patients between early and late abstinence.

Discussion: The study revealed an upregulation of glutamate transporters EAAT2 and EAAT3 during early and late withdrawal in patients with alcohol withdrawal.

Key words

alcohol withdrawal - glutamate - EAAT
 

  • References

  • 1 Gonzalez J, Jurado-Coronel JC, Avila MF et al. NMDARs in neurological diseases: a potential therapeutic target. Int J Neurosci 2015; 125: 315-327
    CrossrefPubMedGoogle Scholar
  • 2 Nakagawa T, Kaneko S. SLC1 glutamate transporters and diseases: psychiatric diseases and pathological pain. Curr Mol Pharmacol 2013; 6: 66-73
    CrossrefPubMedGoogle Scholar
  • 3 Krystal JH, Petrakis IL, Mason G et al. N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacol Ther 2003; 99: 79-94
    CrossrefPubMedGoogle Scholar
  • 4 Holmes A, Spanagel R, Krystal JH. Glutamatergic targets for new alcohol medications. Psychopharmacology (Berl) 2013; 229: 539-554
    CrossrefPubMedGoogle Scholar
  • 5 Rao PS, Sari Y. Glutamate transporter 1: target for the treatment of alcohol dependence. Curr Med Chem 2012; 19: 5148-5156
    CrossrefPubMedGoogle Scholar
  • 6 Spanagel R, Vengeliene V. New pharmacological treatment strategies for relapse prevention. Curr Top Behav Neurosci 2013; 13: 583-609
    PubMedGoogle Scholar
  • 7 Arriza JL, Fairman WA, Wadiche JI et al. Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J Neurosci 1994; 14: 5559-5569
    PubMedGoogle Scholar
  • 8 Danbolt NC. Glutamate uptake. Prog Neurobiol 2001; 65: 1-105
    CrossrefPubMedGoogle Scholar
  • 9 Skerry TM, Genever PG. Glutamate signalling in non-neuronal tissues. Trends Pharmacol Sci 2001; 22: 174-181
    CrossrefPubMedGoogle Scholar
  • 10 Zoia C, Cogliati T, Tagliabue E et al. Glutamate transporters in platelets: EAAT1 decrease in aging and in Alzheimer’s disease. Neurobiol Aging 2004; 25: 149-157
    CrossrefPubMedGoogle Scholar
  • 11 Begni B, Tremolizzo L, D'Orlando C et al. Substrate-induced modulation of glutamate uptake in human platelets. Br J Pharmacol 2005; 145: 792-799
    CrossrefPubMedGoogle Scholar
  • 12 Kryger R, Wilce PA. The effects of alcoholism on the human basolateral amygdala. Neuroscience 2010; 167: 361-371
    CrossrefPubMedGoogle Scholar
  • 13 Sari Y. Potential therapeutic role of glutamate transporter 1 for the treatment of alcohol dependence. OA Alcohol 2013; 1: 6
    PubMedGoogle Scholar
  • 14 Sari Y. Role of glutamate transporter 1 in the attenuation of alcohol intake. Front Neurosci 2014; 8: 200
    PubMedGoogle Scholar
  • 15 Sari Y, Sakai M, Weedman JM et al. Ceftriaxone, a beta-lactam antibiotic, reduces ethanol consumption in alcohol-preferring rats. Alcohol Alcohol 2011; 46: 239-246
    CrossrefPubMedGoogle Scholar
  • 16 Qrunfleh AM, Alazizi A, Sari Y. Ceftriaxone, a beta-lactam antibiotic, attenuates relapse-like ethanol-drinking behavior in alcohol-preferring rats. J Psychopharmacol 2013; 27: 541-549
    CrossrefPubMedGoogle Scholar
  • 17 Sari Y, Sreemantula SN. Neuroimmunophilin GPI-1046 reduces ethanol consumption in part through activation of GLT1 in alcohol-preferring rats. Neuroscience 2012; 227: 327-335
    CrossrefPubMedGoogle Scholar
  • 18 Alhaddad H, Kim NT, Aal-Aaboda M et al. Effects of MS-153 on chronic ethanol consumption and GLT1 modulation of glutamate levels in male alcohol-preferring rats. Front Behav Neurosci 2014; 8: 366
    PubMedGoogle Scholar
  • 19 Selzer ML. The Michigan alcoholism screening test: the quest for a new diagnostic instrument. Am J Psychiatry 1971; 127: 1653-1658
    CrossrefPubMedGoogle Scholar
  • 20 Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389
    CrossrefPubMedGoogle Scholar
  • 21 Sullivan JT, Swift RM, Lewis DC. Benzodiazepine requirements during alcohol withdrawal syndrome: clinical implications of using a standardized withdrawal scale. J Clin Psychopharmacol 1991; 11: 291-295
    PubMedGoogle Scholar
  • 22 Aoyama K, Nakaki T. Neuroprotective properties of the excitatory amino acid carrier 1 (EAAC1). Amino Acids 2013; 45: 133-142
    CrossrefPubMedGoogle Scholar